Why People Keep Taking Semaglutide Despite Serious Side Effects—And What It Reveals About Weight Loss

People taking semaglutide (Ozempic) are willing to endure uncomfortable gastrointestinal side effects as long as the medication delivers meaningful weight loss. A new study analyzing patient experiences reveals that effective weight reduction is the primary driver of satisfaction—outweighing even nausea, vomiting, and digestive complaints that affect more than half of users.

Researchers from Rutgers Robert Wood Johnson Medical School examined 60 publicly available, anonymous user reviews of semaglutide used off-label for weight management. The analysis, published in the Journal of Medical Internet Research, identified three major themes in patient experiences: changes in body weight and appetite, non-weight-related symptoms and side effects, and decisions to continue or stop treatment.

What Drives Patient Satisfaction With Weight Loss Drugs?

The findings paint a clear picture of patient priorities. Two-thirds of respondents reported reduced appetite, fewer food cravings, or noticeable body weight loss. Gastrointestinal complaints—including nausea, vomiting, and digestive issues—occurred frequently, reported by 37 of the 60 participants. Yet these uncomfortable side effects did not significantly influence satisfaction ratings or decisions to continue treatment.

Instead, the strongest predictors of discontinuation were minimal or no weight loss and the emergence of non-gastrointestinal side effects. Patients showed greater willingness to continue semaglutide treatment when they experienced effective weight loss, even when accompanied by significant gastrointestinal discomfort. "What we found is that for many users, the calculus is straightforward: If the drug helps them lose weight, they're willing to tolerate significant discomfort," said Morgan H. James, Ph.D., senior author from Rutgers Robert Wood Johnson Medical School. "That tells us something important about the demand for effective weight loss options and how we need to think about supporting such patients."

The Growing Off-Label Use Problem

This patient tolerance for side effects occurs against a backdrop of rapidly expanding semaglutide use far beyond its original medical purpose. Semaglutide is marketed under two brand names: Ozempic for type 2 diabetes and Wegovy for chronic weight management in people with obesity. However, the medication is increasingly used off-label by non-diabetic individuals seeking weight loss for aesthetic reasons.

The numbers are striking. Global use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—the drug class that includes semaglutide—increased by 594% between 2020 and 2023. Among women aged 18 to 25, the increase reached 659%, while men in the same age group saw a 481% increase. In the United States alone, semaglutide prescriptions jumped 442%, from 471,876 prescriptions to 2,555,308 prescriptions during this period.

More than 7 million prescriptions of GLP-1 receptor agonists were prescribed to individuals without a diabetes diagnosis, signaling widespread off-label use without medical supervision. By 2023, only 68% to 83% of Ozempic users had a clear medical indication for the medication.

Steps to Understanding Your Weight Loss Options

• Consult a healthcare provider: Before starting any weight loss medication, discuss your medical history, current medications, and weight loss goals with a doctor who can determine if semaglutide or other treatments are appropriate for your situation.
• Understand the side effect profile: Know that gastrointestinal side effects like nausea and vomiting are common with GLP-1 medications, but research suggests they often don't prevent people from continuing treatment if weight loss occurs.
• Evaluate non-medication approaches first: Lifestyle modifications including healthy diet and regular exercise remain the main approach to tackling obesity and should be explored before or alongside medication.
• Monitor for non-gastrointestinal side effects: While digestive complaints are common, watch for other side effects that may warrant stopping the medication, as research shows these are more likely to lead to discontinuation.

Why This Matters for Diabetes Patients

The surge in off-label semaglutide use has created a critical access problem. As demand from non-diabetic users increases, supply constraints threaten to exclude patients with type 2 diabetes who genuinely need the medication for blood sugar control. This phenomenon, called "therapeutic exclusion," occurs when patients with legitimate medical needs are deprived of treatment access because resources are diverted toward non-indicated or aesthetic uses.

Pharmaceutical companies are capitalizing on this trend. Novo Nordisk's Ozempic sales are expected to surge 26% in 2024 to $40.5 billion, while Eli Lilly's competing medication is projected to reach $45 billion, a 32% increase. These projections reflect the massive demand from both diabetic and non-diabetic users seeking weight loss.

The research from Rutgers reveals an important insight: patients are willing to tolerate real discomfort for effective weight loss. This underscores the urgent need for robust weight loss treatment options—but also highlights the ethical imperative to ensure equitable access for those with medical indications while implementing stricter regulation of off-label use. Without intervention, experts warn that essential diabetes medications could increasingly function as aesthetic commodities rather than therapeutic necessities.